Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 82.7, BIIB scored 37.7 — ANIP leads.
Compare another set
Different reporting periods. ANIP's fundamentals are as of June 2026, but BIIB's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
ANIP
ANI Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Quality-Growth
82.7
$73.89 · $1.7B
fundamentals as of
Score gap
45.0
ANIP leads
BIIB
Biogen Inc.
Drug Manufacturers - General · Quality-Growth
37.7
$225.71 · $33.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestANIP16.0x
Fastest growthANIP+43.8%
Strongest balance sheetBIIB0.44
Highest qualityANIP66 / 100
Largest discount to fair valueANIP-56%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
BIIB
66
Qualityreturns · margins · balance sheet
58
93
Growthrevenue & earnings expansion
32
92
Valuevaluation vs sector peers
29
ANIP is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ANIP
BIIB
$168mC
FCF
$2.4bB
+43.8%A
Rev
+1.2%C
1.05C
D/E
0.44B
16.0xA-
P/E
40.1xC
1.78C+
PEG
2.25C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
BIIB
56% below
Price vs fair valuelower is cheaper
2% below
~-5%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~2%/yr
+76%
1-yr DCF upside
+5%
+129%
5-yr DCF upside
+2%
+237%
10-yr DCF upside
-3%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 24% from 52-week high of $97.00 — deep drawdown territory. Revenue growing +44% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $105.78 (implying +43% upside).
Moat
ROE 20% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 168% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
BIIBBiogen Inc.
Drug Manufacturers - General · $225.71 · beta 0.09
Why now
Drug Manufacturers - General · market cap $33.3b. Trading near 52-week high of $230.49 — momentum setup, limited technical margin of safety. 31 sell-side analysts rate this a Buy with a mean 1-yr target of $239.02 (implying +6% upside).
Moat
Net margin 14% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 177% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and BIIB diverge
On the headline score the gap is 45.0 points in favor of ANIP. The widest single difference is Value, where ANIP leads by 62.9 points.
ValueANIP 92.0 · BIIB 29.1ANIP +62.9
GrowthANIP 92.6 · BIIB 31.9ANIP +60.7
QualityANIP 66.4 · BIIB 57.7ANIP +8.7
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is ANIP or BIIB the better stock?
ANIP scores higher: ANIP 82.7, BIIB 37.7 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do ANIP and BIIB differ most?
The widest gap is value, where ANIP leads by 63 points on the 0–100 pillar scale. ANIP leads all three pillars, so the gap is broad rather than a single-measure difference.
How are ANIP and BIIB scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.